PMID- 38469314
OWN - NLM
STAT- MEDLINE
DCOM- 20240313
LR  - 20240408
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 15
DP  - 2024
TI  - Prognostic significance of lymphocytic foci composition in minor salivary gland 
      biopsies for severe disease flare and severity in Sjogren's syndrome: a 3-year 
      follow-up cohort study.
PG  - 1332924
LID - 10.3389/fimmu.2024.1332924 [doi]
LID - 1332924
AB  - INTRODUCTION: This was an ambispective cohort study evaluating the prognostic 
      significance of lymphocytic foci and its lymphoid composition in minor salivary 
      gland biopsy (MSGB) for short-term disease flare and severity in Sjogren's 
      syndrome (SS). METHODS: The inclusion criteria comprised individuals meeting the 
      ACR/EULAR 2016 criteria who underwent MSGB with an infiltration of more than 50 
      lymphocytes and received clinical diagnosis between September 2017 and December 
      2018. Patients with inadequate biopsy samples were excluded. The number of 
      lymphocytic foci and their lymphoid composition in MSGB were assessed using 
      immunofluorescence staining. Major organ damage and improvements in the EULAR 
      Sjogren's Syndrome Disease Activity Index (ESSDAI) were measured. Statistical 
      analyses, including Cox and linear regressions, were conducted. RESULTS: A total 
      of 78 patients with at least one lymphocytic focus were included in the study. 
      The presence of higher T-cell counts in lymphocytic foci in MSGB was associated 
      with severe disease flare, and a logarithmic transformation of T-cell count 
      indicated increased risk (HR 1.96, 95% CI 0.91-4.21). Improvements in the ESSDAI 
      were associated with higher total lymphocyte count and T- and B-cell numbers in 
      the lymphoid composition of the lymphocytic foci. Seropositive patients exhibited 
      higher T CD4+ cell numbers. Correlation analysis showed negative associations 
      between age and lymphocytic foci and the T-cell count. Positive correlations were 
      observed between antinuclear antibody (ANA) titers and total lymphocyte numbers. 
      DISCUSSION: Patients with a higher number of T cells in the lymphocytic 
      infiltrates of lymphocytic foci may have a two-fold risk of severe disease flare. 
      The number of B cells and T CD4+ cells in the lymphocytic infiltrates of 
      lymphocytic foci showed a weak but positive relation with the ESSDAI improvement 
      during follow-up. Age and seropositivity appeared to influence the lymphoid 
      composition of the lymphocytic foci.
CI  - Copyright (c) 2024 Park, Martinez-Martinez, Magallares Lopez, Castellvi, Moya, 
      Codes-Mendez, Hernandez Sosa, Diaz-Torne, Laiz, Sainz, Tandaipan, Mariscal, 
      Franco-Leyva, Casademont, Juarez and Corominas.
FAU - Park, Hye-Sang
AU  - Park HS
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Martinez-Martinez, Laura
AU  - Martinez-Martinez L
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Immunology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Magallares Lopez, Berta
AU  - Magallares Lopez B
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Castellvi, Ivan
AU  - Castellvi I
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Moya, Patricia
AU  - Moya P
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Codes-Mendez, Helena
AU  - Codes-Mendez H
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Hernandez Sosa, Nerea
AU  - Hernandez Sosa N
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Internal Medicine 
      Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute 
      (IIB Sant Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Diaz-Torne, Cesar
AU  - Diaz-Torne C
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Laiz, Ana
AU  - Laiz A
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Sainz, Luis
AU  - Sainz L
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Tandaipan, Jose Luis
AU  - Tandaipan JL
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Mariscal, Anais
AU  - Mariscal A
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Immunology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Franco-Leyva, Teresa
AU  - Franco-Leyva T
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Immunology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Casademont, Jordi
AU  - Casademont J
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Internal Medicine 
      Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute 
      (IIB Sant Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Juarez, Candido
AU  - Juarez C
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Immunology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
FAU - Corominas, Hector
AU  - Corominas H
AD  - Functional Unit of Systemic Autoimmune Diseases (UFMAS), Rheumatology Department, 
      Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute (IIB Sant 
      Pau), Universitat Autonoma de Barcelona, Barcelona, Spain.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20240226
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - 89022-11-7 (2'-carbomethoxyphenyl 4-guanidinobenzoate)
RN  - 0 (Guanidines)
SB  - IM
MH  - Humans
MH  - *Salivary Glands, Minor/pathology
MH  - *Sjogren's Syndrome
MH  - Follow-Up Studies
MH  - Prognosis
MH  - Cohort Studies
MH  - Symptom Flare Up
MH  - B-Lymphocytes/pathology
MH  - Biopsy
MH  - Inflammation/pathology
MH  - *Guanidines
PMC - PMC10925694
OTO - NOTNLM
OT  - Sjogren's syndrome
OT  - fluorescent antibody technique
OT  - histopathology
OT  - immunofluorescence staining
OT  - lip biopsy
OT  - lymphocyte infiltration
OT  - lymphoid organization
OT  - minor salivary gland biopsy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/12 06:43
MHDA- 2024/03/13 06:46
PMCR- 2024/01/01
CRDT- 2024/03/12 03:54
PHST- 2023/11/03 00:00 [received]
PHST- 2024/01/23 00:00 [accepted]
PHST- 2024/03/13 06:46 [medline]
PHST- 2024/03/12 06:43 [pubmed]
PHST- 2024/03/12 03:54 [entrez]
PHST- 2024/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2024.1332924 [doi]
PST - epublish
SO  - Front Immunol. 2024 Feb 26;15:1332924. doi: 10.3389/fimmu.2024.1332924. 
      eCollection 2024.